Adgero Biopharmaceuticals Holdings Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Adgero Biopharmaceuticals Holdings Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11081
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:30
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥33,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥67,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥100,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Adgero Biopharmaceuticals Holdings Inc (Adgero), formerly Adgero Biopharmaceuticals Inc is a biopharmaceutical company that develops proprietary late stage photodynamic therapy platform for the treatment of oncology indications. The company’s pipeline products include REM-001. Its product is used for the treatment of cutaneous metastatic breast cancer, bile duct cancer, cutaneous metastatic ovarian and colon cancers, recurrent basal cell carcinoma nevus syndrome, advanced basal cell carcinoma, cutaneous T-cell lymphoma and Merkel cell carcinoma. Adgero’s REM-001 treats CMBC tumors in multiple prior phases 2 and 3 clinical trials. The company’s PDT technology induces elimination of diseased cells by immune response, apoptosis, antiangiogenesis and necrosis. Adgero is headquartered in Princeton, New Jersey, the US.

Adgero Biopharmaceuticals Holdings Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Adgero Biopharmaceuticals Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Adgero Biopharmaceuticals Holdings Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Adgero Biopharmaceuticals Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Adgero Biopharmaceuticals Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Adgero Biopharmaceuticals Holdings Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Adgero Biopharmaceuticals Holdings Inc, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Adgero Biopharma Acquires Certain Assets and Regulatory Filings from Miravant Medical Technologies 10
Venture Financing 11
Adgero Biopharma Raises USD0.5 Million in Venture Financing 11
Adgero Biopharma Raises USD3 Million Financing 12
Adgero Biopharma Raises Funds through Venture Financing 13
Equity Offering 14
Adgero Biopharma Raises USD3.4 Million in Private Placement of Shares upon Exercise of Warrants 14
Adgero Biopharma Raises USD2 Million in Equity Financing 15
Adgero Biopharma to Raise Funds in Private Placement of Shares and Warrants 16
Adgero Biopharma Raises USD2 Million in Private Placement of Shares 17
Adgero Biopharma Raises USD9.7 Million in Equity Financing 18
Debt Offering 19
Adgero Biopharma Raises USD0.3 Million in Private Placement of 6% Notes Due 2016 19
Adgero Biopharma Raises Funds in Private Placement of 6% Notes Due 2016 20
Adgero Biopharma Raises Funds in Private Placement of 6% Notes Due 2016 21
Adgero Biopharmaceuticals Holdings Inc – Key Competitors 22
Adgero Biopharmaceuticals Holdings Inc – Key Employees 23
Adgero Biopharmaceuticals Holdings Inc – Locations And Subsidiaries 24
Head Office 24
Recent Developments 25
Corporate Communications 25
Oct 25, 2017: Adgero Biopharmaceuticals Appoints John Liatos as Chief Financial Officer 25
Sep 14, 2017: Adgero Biopharmaceuticals Appoints Felix T. Garzon, M.D., Ph.D. as Chief Medical Officer 26
Feb 14, 2017: Adgero Biopharmaceuticals Holdings, Inc. Expands Executive Management Team with Appointment of Jane M. Maida as Chief Financial Officer 27
Product News 28
01/26/2017: Adgero Biopharmaceuticals to Present at Noble Capital Markets’ Thirteenth Annual Investor Conference 28
Clinical Trials 29
Apr 10, 2017: Positive Clinical Data of Adgero Biopharmaceuticals’ REM-001 Therapy for the Treatment of Cutaneous Metastatic Breast Cancer Presented at 37th ASLMS Annual Conference 29
Appendix 30
Methodology 30
About GlobalData 30
Contact Us 30
Disclaimer 30

List of Tables
Adgero Biopharmaceuticals Holdings Inc, Pharmaceuticals & Healthcare, Key Facts 2
Adgero Biopharmaceuticals Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Adgero Biopharmaceuticals Holdings Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Adgero Biopharmaceuticals Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Adgero Biopharmaceuticals Holdings Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Adgero Biopharmaceuticals Holdings Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Adgero Biopharma Acquires Certain Assets and Regulatory Filings from Miravant Medical Technologies 10
Adgero Biopharma Raises USD0.5 Million in Venture Financing 11
Adgero Biopharma Raises USD3 Million Financing 12
Adgero Biopharma Raises Funds through Venture Financing 13
Adgero Biopharma Raises USD3.4 Million in Private Placement of Shares upon Exercise of Warrants 14
Adgero Biopharma Raises USD2 Million in Equity Financing 15
Adgero Biopharma to Raise Funds in Private Placement of Shares and Warrants 16
Adgero Biopharma Raises USD2 Million in Private Placement of Shares 17
Adgero Biopharma Raises USD9.7 Million in Equity Financing 18
Adgero Biopharma Raises USD0.3 Million in Private Placement of 6% Notes Due 2016 19
Adgero Biopharma Raises Funds in Private Placement of 6% Notes Due 2016 20
Adgero Biopharma Raises Funds in Private Placement of 6% Notes Due 2016 21
Adgero Biopharmaceuticals Holdings Inc, Key Competitors 22
Adgero Biopharmaceuticals Holdings Inc, Key Employees 23

List of Figures
Adgero Biopharmaceuticals Holdings Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Adgero Biopharmaceuticals Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Adgero Biopharmaceuticals Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Adgero Biopharmaceuticals Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Adgero Biopharmaceuticals Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Adgero Biopharmaceuticals Holdings Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Adgero Biopharmaceuticals Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Adgero Biopharmaceuticals Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Adgero Biopharmaceuticals Holdings Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Ferrexpo Plc:企業の戦略・SWOT・財務情報
    Ferrexpo Plc - Strategy, SWOT and Corporate Finance Report Summary Ferrexpo Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • CEL-SCI Corp (CVM)-製薬・医療分野:企業M&A・提携分析
    Summary CEL-SCI Corp (CEL-SCI) is a biotechnology company that carries out the research and development of new immunotherapy products for the treatment of various cancer and infectious diseases. Its core capabilities include drug discovery, research, development and manufacturing of compound biologi …
  • Hycrete Inc:企業の戦略的SWOT分析
    Hycrete Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • CryoPort Inc (CYRX):企業の財務・戦略的SWOT分析
    CryoPort Inc (CYRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Extreme Networks Inc (EXTR):企業の財務・戦略的SWOT分析
    Extreme Networks Inc (EXTR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Petrogas E&P LLC:石油・ガス:M&Aディール及び事業提携情報
    Summary Petrogas E&P LLC (Petrogas), a subsidiary of MB Holding Company LLC, is an oil and gas company that offers crude oil exploration and development services. The company explores and produces crude oil, natural gas, and other petroleum products. It holds interest in oil producing areas in onsho …
  • Anagin Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Anagin Inc (Anagin) formerly Anagin LLC, is a biotechnology company which develops novel targeted therapies for the treatment of neuropsychiatric diseases. The company is focused on the development of first-in-class small molecule modulators of neurotransmitter signaling complexes that reduc …
  • Sun-Rype Products Ltd.:企業の戦略・SWOT・財務情報
    Sun-Rype Products Ltd. - Strategy, SWOT and Corporate Finance Report Summary Sun-Rype Products Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Chemring Group PLC:企業のM&A・事業提携・投資動向
    Chemring Group PLC - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Chemring Group PLC Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • Nestle USA, Inc.:企業の戦略・SWOT・財務情報
    Nestle USA, Inc. - Strategy, SWOT and Corporate Finance Report Summary Nestle USA, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • The Walter and Eliza Hall Institute of Medical Research-製薬・医療分野:企業M&A・提携分析
    Summary The Walter and Eliza Hall Institute of Medical Research (WEHI), a subsidiary of Melbourne Medical School The University of Melbourne is a medical research institute that conducts clinical research, and offers educational and contract research services. The institute develops therapeutics for …
  • Kaiser Foundation Health Plan of Washington:企業の戦略的SWOT分析
    Kaiser Foundation Health Plan of Washington - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors a …
  • amcure GmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary Amcure GmbH (Amcure) is a biopharmaceutical company that discovers and develops therapeutics for the treatment of cancer. The company develops peptide-based compounds for the treatment of metastatic forms of cancer. Its lead candidate, AMC303 is used for the treatment of metastatic epithelia …
  • Embera NeuroTherapeutics Inc-製薬・医療分野:企業M&A・提携分析
    Summary Embera NeuroTherapeutics Inc (Embera) is a contract research company that discovers and develops new treatments. The company’s product includes EMB-001, a drug combination for the stress response system and specific brain functions that results in craving and improvement associated with thes …
  • PPL Corporation:企業の戦略・SWOT・財務情報
    PPL Corporation - Strategy, SWOT and Corporate Finance Report Summary PPL Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • BellBrook Labs LLC:医療機器:M&Aディール及び事業提携情報
    Summary BellBrook Labs LLC (BellBrook) is a medical device company that develops detection reagents and screening tools. The company’s biochemical assay technology offers UVO microconduit array platform, chemotaxis assay plate, transcreener HTS assays, ADP² assays, AMP² and GMP² assays, GDP assays a …
  • J.Crew Group, Inc.:企業の戦略・SWOT・財務分析
    J.Crew Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary J.Crew Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • BBA Aviation plc (BBA):企業の財務・戦略的SWOT分析
    BBA Aviation plc (BBA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Krispy Kreme Doughnuts, Inc.:企業の戦略的SWOT分析
    Krispy Kreme Doughnuts, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Breckenridge Pharmaceutical Inc-製薬・医療分野:企業M&A・提携分析
    Summary Breckenridge Pharmaceutical Inc (Breckenridge), a subsidiary of Laboratorios Del Dr Esteve SA is a healthcare solution provider that research, develops and markets various generic prescription products. The company provides products including stradiol, oxcarbazepine tablets, methylprednisolo …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆